Navigation Links
AbGenomics International, Inc. Regains Global Rights to AbGn-168H from Boehringer Ingelheim

LOS ALTOS, Calif., Dec. 16, 2011 /PRNewswire-iReach/ -- AbGenomics International, Inc. today announced that, effective February 13, 2012, it will regain global rights to AbGn-168H, a humanized monoclonal antibody against CD-162, as part of an agreed–upon arrangement following the termination of its collaboration with Boehringer Ingelheim, Germany. AbGn-168H preferentially induces apoptosis of late-stage activated T-cells and is being developed for the treatment of psoriasis and other immunological diseases.


Data are available from two phase one clinical trials under this development program. AbGenomics plans to continue the development of AbGn-168H in psoriasis as well as in other immune and inflammatory disease indications and will therefore seek a new partner. 

"AbGenomics has had an excellent collaboration with Boehringer Ingelheim since 2005," said Dr. Rong-Hwa Lin, founder and CEO of AbGenomics. We greatly appreciate the many contributions of the Boehringer Ingelheim team particularly with respect to its development and manufacture of the drug substance and drug product as well as advancing the program into the clinical trial stage. We also appreciate their support during this transition period as we continue the preparations for the next clinical trial."

"We believe that the unique mechanism of action of AbGn-168H is applicable to a wide variety of immunological diseases," said Dr. Lin. "While we will continue to develop AbGn-168H for psoriasis, regaining the global rights will also permit us to consider other indications that will take advantage of the full therapeutic potential of this drug."

About AbGenomics (

AbGenomics is a biopharmaceutical company focused on the discovery and development of novel medicines to treat diseases with unmet medical need and significant market potential. Currently, the company has two therapeutic candidates in clinical trials. Headquartered in San Francisco Bay Area, U.S., AbGenomics has subsidiaries in the Netherlands and in Taiwan. The Company's strategy is to commercialize its novel products in collaboration with major pharmaceutical partners in order to maximize the opportunity for development and marketing of the Company's compounds. 


News distributed by PR Newswire iReach:




SOURCE AbGenomics International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Arno Therapeutics, Inc. Completes $18 Million Financing and Reverse Merger with Laurier International, Inc.
2. Medizone International, Inc. (MZEI.PK): Trials of the AsepticSure Hospital Sterilization System Have Begun
3. Chindex International, Inc. to Report Second Quarter Fiscal 2010 Financial Results
4. Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results
5. Natural Alternatives International, Inc. Announces Filing of Patent Infringement Lawsuit
6. DATATRAK International, Inc. Announces Year-End Backlog
7. New Database from ANSI, AAMI, ASTM International, and DIN Provides Centralized Source of Information for Medical Device Professionals
8. DAVISCO Foods International, Inc. and MEGGLE Group Announce a Joint Venture for the Production of Pharmaceutical Lactose.
9. Lexington International, LLC Receives 2009 U.S. Presidents E Award Recognizing its Export Achievements
10. International, Well-Known Scientific Experts Say That New GFT505 Data Unlikely to Have the Potential to Affect the Established Role of Generic Fenofibrate and Bezafibrate in Managing Atherogenic Dyslipidemia
11. International Growth Continues: Rhythmlink International, LLC Receives CE Marking & ISO 13485 Certification
Post Your Comments:
(Date:12/1/2015)... -- ) has announced ... Market 2015 - Forecast to 2020" report ... has announced the addition of the "Drug ... report to their offering. --> ... the addition of the "Drug Delivery Technology ...
(Date:12/1/2015)... Sweden , December 1, 2015 ... Cancer Study Group (IBCSG, Bern ) and ... to be part of a state of the art trial, ... --> --> The study, ... treated with anti-hormonal therapy in combination with palbociclib, a cancer ...
(Date:11/30/2015)... BASEL, Switzerland , Dec. 1, 2015 /PRNewswire/ ... its wholly-owned UK subsidiary Proximagen Ltd., today announced a ... oral small molecule inhibitor of Vascular Adhesion Protein 1 ... the treatment of inflammatory disease. The VAP-1 inhibitor is ... --> --> Under the terms of ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... For the ... is why Hollister Incorporated has launched the VaPro Plus Pocket™ touch free hydrophilic ... the VaPro touch free catheter portfolio,” said Michael Gresavage, Vice President North America. ...
(Date:12/1/2015)... ... ... McLean, VA., December 1, 2015 - Octo Consulting Group, ... development contract to support the National Geospatial-Intelligence Agency's (NGA) IT Services Directorate. ... as well as operations and sustainment support to the NGA’s Agile Web Presence ...
(Date:12/1/2015)... ... ... XTC Semifinals 2016 - CES, Las Vegas, Nevada - Extreme ... 2016, the world’s largest Consumer Electronic Show, where they will present to a panel ... Pacific Investments Veronica Serra, and venture capitalist Tim Draper among many other top names ...
(Date:12/1/2015)... ... December 01, 2015 , ... Dr. Arash ... Modern Man for 2015. , Angeleno Magazine is a division of Modern ... in 1994, Modern Luxury includes more than 50 magazine titles across 15 major ...
(Date:11/30/2015)... ... 2015 , ... Olympic Gold Medalists and Celebrity Moms Dara ... various categories through traditional and social media marketing campaigns and other branding initiatives. ... Medal Moms who can connect with today’s most important consumer: mothers. In addition ...
Breaking Medicine News(10 mins):